Introduction
Ipamorelin, a pentapeptide, demonstrates interesting potency and efficacy in stimulating growth hormone (GH) release, both in laboratory studies and in living organisms.
In both animal and human research studies, ipamorelin is believed to raise plasma growth hormone (GH) levels. Furthermore, ipamorelin may also promote body weight increase in animals. Ipamorelin, like pralmorelin and GHRP-6, has no effect on prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.
To date, Ipamorelin is not an FDA-approved research drug. For this very reason, buy Ipamorelin for laboratory research use only.
Ipamorelin Product Details
Ipamorelin, a research peptide, possesses the specific ability to stimulate the release of growth hormone (GH). Composed of five amino acids, it is classified as a pentapeptide. The chemical under consideration is identified as a ghrelin-mimetic ipamorelin since it binds to the ghrelin receptors in the brain increasing GH release from the pituitary gland preferentially.
Although often grouped with CJC 1295, it is important to note that Ipamorelin and CJC 1295 are distinct compounds.
Originally developed by Novo Nordisk Inc., Ipamorelin underwent phase 2 trials as a potential treatment for postoperative ileus, a condition characterized by the temporary cessation of bowel function following surgical procedures. Unfortunately, these trials revealed a lack of efficacy, leading to the discontinuation of its development.
Through pharmacological profiling using growth hormone-releasing peptide (GHRP) and growth hormone-releasing hormone (GHRH) antagonists, it has been demonstrated by some studies that Ipamorelin stimulates the release of GH by interacting with a receptor similar to that of GH. The selectivity of Ipamorelin for GH release mirrors that of GHRH, further highlighting its pharmacological potential.
Even though this compound could potentially offer certain health advantages, more studies are needed to understand the growth hormone secretagogue effects of Ipamorelin.
- CAS number 170851-70-4
- Molar Mass 711.868 g·mol−1
- Chemical Formula C38H49N9O5
- IUPAC Name (2S)-6-Amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4H-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Key Features of Ipamorelin for Sale
- 98% Purity
- 2mg / 5mg
- Sold for research purposes only
Potential Benefits of Ipamorelin
Ipamorelin and Muscle Growth
In a study focusing on the catabolic effects of glucocorticoids on skeletal muscle and bones among steroid-treated rats, Ipamorelin demonstrated its potential to counteract these negative effects. The decrease in muscle strength and bone formation observed in rats injected with glucocorticoids was effectively mitigated by Ipamorelin administration. These findings highlight the potential of Ipamorelin as an agent to promote muscle growth and bone health. [R]
Ipamorelin and Glucocorticoids
Glucocorticoids (GCs) are naturally occurring steroids that play various roles in the body, including managing inflammation and treating inflammation-related conditions. However, they can also have adverse effects such as weight gain, water retention, and muscle weakness. In an adult rat model, the effects of Ipamorelin on counteracting the catabolic effects of GCs on skeletal muscles and bones were investigated. [R]
Over a three-month period, female rats were given GC (methylprednisolone), GHS (ipamorelin), or both. The study revealed that the administration of Ipamorelin alongside GCs mitigated the decrease in muscle strength and bone formation caused by GCs. These results support the potential therapeutic use of growth hormone secretagogues (GHSs) in participants receiving glucocorticoid treatment. [R]
Ipamorelin and Weight Gain
In a 9-week animal study involving GH-deficient and GH-intact female mice, the impact of Ipamorelin on adiposity and weight gain was evaluated. The GH-deficient mice treated with Ipamorelin experienced a significant 15.3% increase in body weight. Notably, there were no observed changes in the relative weight of dissected organs, unlike treatment with GH, which resulted in increased liver weight. This suggests that Ipamorelin treatment may not lead to organomegaly, a common side effect seen in GH-treated patients. [R]
Ipamorelin and Diabetes
Research suggests that Ipamorelin can effectively stimulate insulin secretion from the pancreas of both normal and diabetic rats. It achieves this by stimulating insulin release through the calcium channel and adrenergic receptor pathways. A study investigating the effects of Ipamorelin on insulin secretion from pancreatic tissue fragments of normal and diabetic rats provided these insights. [R]
Ipamorelin and Bone Health
Studies conducted on adult female rats demonstrated the positive effects of Ipamorelin and GH-releasing peptide-6 on bone health. Both Ipamorelin and GHRP-6 increased total, tibial, and vertebral bone mineral content in vivo when compared to the control group. Furthermore, these substances also increased tibial area bone mineral density. Another study focusing on adult female rats found that Ipamorelin had a dose-dependent effect on the longitudinal bone growth rate (LGR) and body weight gain. These findings indicate the potential of Ipamorelin to promote bone health and growth. [R]
It is important to note that while these studies provide valuable insights into the effects of Ipamorelin, further investigation through longer-term clinical trials involving randomized populations is necessary to fully understand and confirm its potential anabolic effects as a growth hormone secretagogue. [R]
How It Works
Ipamorelin exerts its mechanism of action by effectively mimicking the functions of ghrelin, a hormone primarily found in the gut, which influences various physiological processes including food intake, fat deposition, and growth hormone (GH) release. By binding to the ghrelin receptor, also known as the GH secretagogue receptor (GHSR), located in the brain, Ipamorelin selectively triggers the release of GH from the pituitary gland.
Extensive research has demonstrated that GH secretion tends to decrease as individuals age. This decline in GH secretion, along with a reduction in insulin-like growth factor-1 (IGF-1), has been associated with the age-related decrease in lean body mass and the concurrent increase in adipose tissue. Ipamorelin’s ability to stimulate GH release presents an avenue for potentially addressing these age-related changes, offering a possible strategy to counteract the decline in GH and promote favorable alterations in body composition.
Precautions
When researching the use of Ipamorelin, it is essential to take certain precautions. Here are some precautions to keep in mind:
Observe best practices for studying research chemicals: Studying research chemicals requires a responsible and informed approach to ensure safety and meaningful scientific exploration. Research chemicals, also known as designer drugs or experimental compounds, are substances synthesized for scientific investigation or exploration of their properties.
Follow recommended dosage: Adhere to the recommended dosage instructions outlined on the product label. Avoid exceeding the suggested dose to minimize the risk of potential adverse effects among test subjects.
Safety and Side Effects
Ipamorelin is generally well tolerated, but participants should be aware of potential side effects. Injection site reactions, headaches, nausea, and flushing were the most commonly reported side effects. Dizziness, abdominal discomfort, and fatigue are less common side effects.
Conclusion
In conclusion, the utilization of Ipamorelin holds considerable promise in various areas of scientific research and therapeutic applications. As a selective growth hormone secretagogue, Ipamorelin offers a unique approach to modulating the release of growth hormone (GH) from the pituitary gland. Its resemblance to ghrelin, a gut hormone, enables it to bind to ghrelin receptors and stimulate GH secretion, providing a valuable alternative to traditional growth hormone therapies.
Studies conducted on animal models explain that Ipamorelin evoked insulin release among its test subjects. Furthermore, this research chemical has been shown to enhance bone formation, counteracting the detrimental effects of steroids on skeletal muscles and bones. Additionally, Ipamorelin exhibits ghrelin-mimetic properties, triggering the release of insulin and promoting bone density, nitrogen balance, and muscle growth. These findings underline the potential of Ipamorelin in the treatment of conditions such as muscle wasting, bone loss, and autoimmune diseases.
Its potential applications extend beyond hormone therapies, including peptide research, laboratory use, and even positron emission tomography studies. As a research chemical available for sale, Ipamorelin offers scientists and researchers a valuable tool for investigating the intricacies of growth hormone regulation, and its interactions with the androgen receptor, prolactin, follicle-stimulating hormone, and other key factors.
Disclaimer:
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before making a purchase from RCD.bio. By completing your order and submitting payment, you agree to abide by the Terms and Conditions of our company. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If for any reason you are not completely satisfied with the product you receive, please contact us at [email protected]. Our team is dedicated to ensuring satisfaction among our customers.
PLEASE NOTE: Consistent with its aim to be the best research compound supplier, all products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.
